FDA advisors unanimously snub Pfizer's Talzenna in broader prostate cancer population
Eight outside experts on the FDA’s Oncologic Drugs Advisory Committee delivered a unanimous ‘No’ vote on the question of whether Pfizer’s PARP inhibitor Talzenna has a favorable benefit-risk profile in metastatic castration-resistant prostate cancer patients without homologous recombination repair gene mutations.
Eight outside experts on the FDA’s Oncologic Drugs Advisory Committee delivered a unanimous ‘No’ vote on the question of whether Pfizer’s PARP inhibitor Talzenna has a favorable benefit-risk profile in metastatic castration-resistant prostate cancer patients without homologous recombination repair gene mutations.
